Pharmacokinetics of cidofovir in monkeys: Evidence for a prolonged elimination phase representing phosphorylated drug

Drug Metabolism and Disposition

Volumn 24, Issue 7, 1996, Pages 738-744

  Cundy, Kenneth C ^a   Li, Zhen Hong ^a,b   Hitchcock, Michael J M ^a   Lee, William A ^a  

^a GILEAD SCIENCES   (United States)

^b MEDIMMUNE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIDOFOVIR; PHOSPHORYLCHOLINE; PROBENECID;

ANIMAL EXPERIMENT; ARTICLE; CYTOMEGALOVIRUS INFECTION; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; HERPES; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVENOUS DRUG ADMINISTRATION; MONKEY; NEPHROTOXICITY; NONHUMAN; ORAL DRUG ADMINISTRATION; PHOSPHORYLATION; PRIORITY JOURNAL; RETINITIS; SUBCUTANEOUS DRUG ADMINISTRATION;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, ORAL; ANIMALS; ANTIVIRAL AGENTS; BIOLOGICAL AVAILABILITY; CARBON RADIOISOTOPES; CERCOPITHECUS AETHIOPS; CYTOSINE; INJECTIONS, INTRAVENOUS; MACACA FASCICULARIS; ORGANOPHOSPHORUS COMPOUNDS; PHOSPHONIC ACIDS; PHOSPHORYLATION; PROBENECID; VIRUS DISEASES;

EID: 0030055492     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. J. J. Bronson, L. M. Ferrara, M. J. M. Hitchcock, H.-T. Ho, K. L. Woods, I. Ghazzouli, E. R. Kern, K. F. Soike, and J. C. Martin: (S)-1-(3-Hydroxy-2-(phosphonylmethoxy)propyl) cytosine (HPMPC): a potent antiherpesvirus agent. In "Immunobiology and Prophylaxis of Human Herpesvirus Infections" (C. Lopez et al., eds.), pp. 277-283. Plenum Press, New York, 1990.
2. J. P. Lalezari, G. Holland, R. Stagg, D. Ives, F. Kramer, B. Kuppermann, C. Kemper, M. Youle, R. Lewis, D. Weinberg, M. Johnson, D. Northfelt, W. L. Drew, and H. S. Jaffe: "A Randomized, Controlled Study of Cidofovir for Relapsing Cytomegalovirus in Patients with AIDS." Program Addendum of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy (abstr. LB-9). American Society for Microbiology, Washington, D.C., 1995.
3. T. Cihlar, I. Votruba, K. Horska, R. Liboska, I. Rosenberg, and A. Holy: Metabolism of 1-(S)-(3-hydroxy-2-phosphonomethoxypropyl)-cytosine (HPMPC) in human embryonic lung cells. Collect. Czech. Chem. Commun. 57, 661-672 (1992).
4. H.-T. Ho, K. L. Woods, J. J. Bronson, H. De Boeck, J. C. Martin, and M. J. M. Hitchcock: Intracellular metabolism of the antiherpes agent (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine. Mol. Pharmacol. 41, 197-202 (1991).
5. E. R. Kern: Value of animal models to evaluate agents with potential against human cytomegalovirus. Transplant. Proc. 23, 152-155 (1992).
6. K. C. Cundy, B. P. Petty, J. Flaherty, P. E. Fisher, M. A. Polis, M. Wachsman, P. S. Lietman, M. J. M. Hitchcock, and H. S. Jaffe: Clinical pharmacokinetics of cidofovir in HIV-infected patients. Antimicrob. Agents Chemother. 39, 1247-1252 (1995).
7. M. J. M. Hitchcock, S. A. Lacy, J. R. Lindsey, and E. R. Kern: The cyclic congener of cidofovir has reduced nephrotoxicity in three species. Antiviral Res. 26, A358 (1995).
8. J. P. Lalezari, W. L. Drew, E. Glutzer, C. James, D. Miner, J. Flaherty, P. E. Fisher, K. C. Cundy, J. Hannigan, J. C. Martin, and H. S. Jaffe: HPMPC: results of a phase I/II study of a novel antiviral nucleotide analogue. J. Infect. Dis. 171, 788-796 (1995).
9. N. Bischofberger, M. J. M. Hitchcock, M. S. Chen, D. Barkhimer, K. C. Cundy, K. M. Kent, S. A. Lacy, W. A. Lee, Z.-H. Li, M. Louie, D. B. Mendel, D. S. Smee, and J. L. Smith: Cyclic HPMPC: an intracellular prodrug for HPMPC with improved therapeutic index in vivo. Antimicrob. Agents Chemother. 38, 2387-2391 (1994).
10. R. F. Cunningham, Z. H. Israili, and P. G. Dayton: Clinical pharmacokinetics of probenecid. Clin. Pharmacokinet. 6, 135-151 (1981).
11. K. C. Cundy, Z.-H. Li, and W. A. Lee: Effect of concomitant probenecid on the tissue distribution and urinary excretion of HPMPC in preclinical models. Pharm. Res. 11, (Suppl.) S-449 (1994).
12. 14C]-HPMPC). J. Labelled Comp. Radiopharm. 29, 1217-1221 (1991).
13. A. Holy and I. Rosenberg: Synthesis of 9-(2-phosphonylmethoxyethyl)adenine and related compounds. Collect. Czech. Chem. Commun. 52, 2801-2809 (1987).
14. Statistical Consultants, Inc.: "PCNONLIN®, Version 4.2. Software for the Statistical Analysis of Nonlinear Models on Micros." Statistical Consultants, Inc., Lexington, KY, 1993.
15. A. Akaike: Posterior probabilities for choosing a regression model. Annals Inst. Math. Statist. 30, A9-14 (1978).
16. K. C. Cundy, G. Lynch, J.-P. Shaw, M. J. M. Hitchcock, and W. A. Lee: Distribution and metabolism of intravitreal cidofovir and cyclic HPMPC in rabbits. Current Eye Res. 15, 569-576 (1996).
17. J. P. Holt and E. A. Rhode: Similarity of renal glomerular hemodynamics in mammals. Am. Heart J. 92, 465-472 (1976).
18. B. Tune: Relationship between the transport and toxicity of cephalosporins in the kidney. J. Infect. Dis. 132, 189-194 (1975).
19. M. Wachsmann, B. G. Petty, K. C. Cundy, H. S. Jaffe, P. E. Fisher, A. Pastelak, and P. S. Lietman: Pharmacokinetics, safety and bioavailability of HPMPC (cidofovir) in HIV-infected subjects. Antiviral Res. 29, 153-161 (1996).
20. W. A. Lee, J.-P. Shaw, A. M. Bidgood, G. Lynch, E. Eisenberg, and K. C. Cundy: Tissue distribution and bioavailability of cyclic HPMPC, an intracellular prodrug of HPMPC. Antiviral Res. 26, A340 (1995).